// App-Quantinova.ai

OP0233 : EFFICACY, SAFETY, AND PHARMACODYNAMIC EFFECTS OF THE BRUTON’S TYROSINE KINASE INHIBITOR, FENEBRUTINIB (GDC-0853), IN MODERATE TO SEVERE SYSTEMIC LUPUS ERYTHEMATOSUS IN A PHASE 2 CONTROLLED STUDY

Researchers

Presenter

  • D. Isenberg

Principal Investigators

  • N. S. Jones

  • P. Guibord

  • J. Galanter

  • C. Lee

  • A. Mcgregor

  • B. Toth

  • J. Rae

  • O. Hwang

  • A. Lokku

  • P. Miranda

  • V. De Souza

  • J. Jaller-Raad

  • A. Maura Fernandes

  • R. Garcia Salinas

  • L. Chinn

  • M. J. Townsend

  • A. Morimoto

  • K. Tuckwell

Medical Centers

  • Kings College London, London, United Kingdom

  • Division of Rheumatology, Northwell Health, Great Neck, United States of America

  • Genentech, Inc., South San Francisco, California, United States of America

  • Hoffmann-La Roche Ltd, Mississauga, ON, Canada

  • Centro De Estudios Reumatologicos, Santiago, Chile

  • Centro Mineiro de Pesquisas, Juiz de Fora, Minas Gerais, Brazil

  • Centro de Reumatologia y Ortopedia, Barranquilla, Colombia

  • Mario Covas Hospital, Santo Andre, Brazil

  • Hospital Italiano de La Plata, Argentina, Argentina

Locations

  • United Kingdom

  • United States

  • Canada

  • Chile

  • Brazil

  • Colombia

  • Argentina

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Lupus

Biomarkers

  • Albumin/creatinine

Drug/Treatment

  • Fenebrutinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Pharmacodynamics

  • Controlled

Phase

  • II

Study Id's

  • N/A

Sponsors

  • AstraZeneca.

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved